Skip to main content
Clinical Trials/IRCT201706176907N13
IRCT201706176907N13
Completed
Phase 2

Evaluation of the efficacy of allogeneic umbilical cord derived hematopoietic and mesenchymal stem cells on developmental functions of spastic cerebral palsy patients between 4-14 years old in comparison with control group , A Clinical trial phase II

Tehran University of Medical Sciences0 sites108 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
108
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Spastic cerebral palsy (Diparetic , Quadriparetic)
  • Ages between 4 \- 14 years
  • Gross motor function classification (GMFC) between 2 \-5
  • No seizure disorder or with controlled seizure
  • Evidence of definite acquired abnormal imaging findings compatible with Cerebral Palsy
  • Informed consent taken from their parents

Exclusion Criteria

  • Normal brain MRI
  • Progressive neurological diseases ( for example leukodystrophy or neurometabolic disorders)
  • Congenital Cortical malformations
  • Toxoplasmosis Others Rubella Cytomegalovirus Hepatitis (TORCH) infections
  • Other types of cerebral palsy including athetoid , atonic , ataxic , and mixed type
  • Acute intercurrent infections such as Hepatitis C Virus ( HCV), Hepatitis B Virus (HBV) ,Human Immunodeficiency Virus (HIV)
  • Hemorrhagic diathesis
  • Severe anemia ( Hemoglobin less than 8 )
  • Ventilator dependent pulmonary diseases
  • Renal insufficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials